DealAjax Therapeutics, a New York and Cambridge, MA-based blood cancer drug developer, was acquired for up to $2.3 billion by Eli Lilly and Company.
More on MedCity News →
M&A
06/19/2026
Moadna, a Syria-based clinic management and booking platform, raised...
OffPlan, an Atlanta-based membership-based primary care platform, raised...
Clair Health, a San Francisco-based women’s hormone-tracking wearable,...
Clario, a Menlo Park, CA-based enterprise data cleanup platform, raised $6...
Houdini Bio, a London-based gene therapy durability platform, raised £1.5...
Rocapine, a Paris-based AI-native wellness venture studio, raised $13...
Stay informed on industry shifts, deal trends, and career opportunities in venture capital.
